Daniel Molin
Consultant at Institutionen för immunologi, genetik och patologi; Forskningsprogram: Cancerimmunterapi; Forskargrupp Gunilla Enblad
- Mobile phone:
- +46 70 204 74 18
- E-mail:
- daniel.molin@igp.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
- ORCID:
- 0009-0005-6662-4865
More information is available to staff who log in.
Short presentation
Chairman of The Swedish Lymphoma Group (SLG) and The Swedish Hodgkin Lymphoma Group.
Head of the lymphoma team, Uppsala University hospital.
Clinical and translational research in lymphoma, especially Hodgkin lymphoma.
Publications
Selection of publications
- Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial (2024)
- Five-year follow-up of KEYNOTE-087 (2023)
- NLPHL (2023)
- Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy (2022)
- Pembrolizumab in relapsed or refractory Richter syndrome (2020)
- No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy (2020)
- Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma (2018)
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma (2017)
- Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 (2017)
Recent publications
- Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial (2024)
- Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors (2024)
- Five-year follow-up of KEYNOTE-087 (2023)
- Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study (2023)
- NLPHL (2023)
All publications
Articles
- Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial (2024)
- Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors (2024)
- Five-year follow-up of KEYNOTE-087 (2023)
- Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study (2023)
- NLPHL (2023)
- Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma (2023)
- Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue (2022)
- Checkpoint CD47 expression in classical Hodgkin lymphoma (2022)
- Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity (2022)
- An image registration method for voxel-wise analysis of whole-body oncological PET-CT (2022)
- Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy (2022)
- Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls (2022)
- High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors? (2021)
- Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma (2021)
- Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders (2021)
- Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma (2021)
- Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma (2021)
- Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma (2021)
- Pembrolizumab in relapsed or refractory Richter syndrome (2020)
- Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma (2020)
- Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy (2020)
- CD30 expression and survival in posttransplant lymphoproliferative disorders (2020)
- No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy (2020)
- Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy (2020)
- Pembrolizumab in relapsed or refractory Hodgkin lymphoma (2019)
- High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms (2019)
- Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation (2019)
- Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma (2019)
- Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy (2019)
- Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome. (2018)
- Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma (2018)
- An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome (2018)
- Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome? (2018)
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma (2017)
- High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome (2017)
- Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 (2017)
- PET-CT for staging and early response (2016)
- Hodgkin Lymphoma In Children, Adolescents And Young Adults-A Comparative Study Of Clinical Presentation And Treatment Outcome (2016)
- The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children (2016)
- High Expression Of Programmed Cell Death Receptor 1 In The Tumor Microenvironment Is Associated With Inferior Event Free Survival In Classical Hodgkin Lymphoma (2016)
- Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment (2016)
- No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission (2016)
- The Importance Of Bone Marrow 18F-Fdg Uptake And Focal Skeletal Lesions On Survival In Patients With Newly Diagnosed Hodgkin Lymphoma (2016)
- Hodgkin Lymphoma In Sweden Since 2000 (2016)
- Expression of Intratumoral Forkhead Box Protein 3 in Posttransplant Lymphoproliferative Disorders (2015)
- Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes (2015)
- Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma (2014)
- Vanishing bile duct-like syndrome in a patient with Hodgkin lymphoma (2014)
- A population-based study of 135 lymphomas after solid organ transplantation (2014)
- Tissue microarray and digital image analysis (2012)
- Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients (2011)
- Long term risk of infections in Hodgkin lymphoma long-term survivors (2011)
- The effect of Eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines (2011)
- Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's Lymphoma (2011)
- Pediatric Organ Transplantation and Risk of Premalignant and Malignant Tumors in Sweden (2011)
- A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3) (2010)
- Framgångens baksida (2010)
- Framgångens baksida (2010)
- Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma (2010)
- Mast cells in squamous cell esophageal carcinoma and clinical parameters (2010)
- Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma (2008)
- The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma (2007)
- Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma (2007)
- Cigarette smoking and risk of Hodgkin lymphoma (2007)
- Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma (2007)
- IL-9 expression contributes to the cellular composition in Hodgkin lymphoma (2006)
- Angiogenesis and mast cells in Hodgkin lymphoma (2005)
- Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). (2005)
- Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. (2004)
- Increased serum levels of Interleukin-9 correlates with negative prognostic factors in Hodgkin's lymphoma (2003)
- Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma (2002)
- Plasma Protein Profiling using Multiplex Extension Assay in Diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP
- Second cancer is the leading cause of death, with no increase of cardiovascular deaths, after combined modality Hodgkin lymphoma treatment
- Real-life data on morbidity and cause-specific mortality after combined modality treatment for Hodgkin lymphoma 2006-2015.
